BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 25625510)

  • 21. Willingness to Pay for One Additional Quality Adjusted Life Year: A Population Based Survey from China.
    Ye Z; Abduhilil R; Huang J; Sun L
    Appl Health Econ Health Policy; 2022 Nov; 20(6):893-904. PubMed ID: 35934772
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Willingness to pay per quality-adjusted life year for life-saving treatments in Thailand.
    Nimdet K; Ngorsuraches S
    BMJ Open; 2015 Oct; 5(10):e008123. PubMed ID: 26438135
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Disentangling WTP per QALY data: different analytical approaches, different answers.
    Gyrd-Hansen D; Kjaer T
    Health Econ; 2012 Mar; 21(3):222-37. PubMed ID: 21254305
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Willingness-to-Pay for One Quality-Adjusted Life-Year: A Population-Based Study from Iran.
    Lankarani KB; Ghahramani S; Moradi N; Shahraki HR; Lotfi F; Honarvar B
    Appl Health Econ Health Policy; 2018 Dec; 16(6):837-846. PubMed ID: 30123949
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Determination of Cost-Effectiveness Threshold for Health Care Interventions in Malaysia.
    Lim YW; Shafie AA; Chua GN; Ahmad Hassali MA
    Value Health; 2017 Sep; 20(8):1131-1138. PubMed ID: 28964445
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The value of a QALY towards the end of life and its determinants: Experimental evidence.
    Fischer B; Telser H; Zweifel P; von Wyl V; Beck K; Weber A
    Soc Sci Med; 2023 Jun; 326():115909. PubMed ID: 37121067
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The value of dementia care towards the end of life-A contingent valuation study.
    Bhattarai N; Mason H; Kernohan A; Poole M; Bamford C; Robinson L; Vale L
    Int J Geriatr Psychiatry; 2020 May; 35(5):489-497. PubMed ID: 31912572
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Willingness to pay for a quality-adjusted life year: implications for societal health care resource allocation.
    King JT; Tsevat J; Lave JR; Roberts MS
    Med Decis Making; 2005; 25(6):667-77. PubMed ID: 16282217
    [TBL] [Abstract][Full Text] [Related]  

  • 29. QALY-type preference and willingness-to-pay among end-of-life patients with cancer treatments: a pilot study using discrete choice experiment.
    Yin Y; Peng Q; Ma L; Dong Y; Sun Y; Xu S; Ding N; Liu X; Zhao M; Tang Y; Mei Z; Shao H; Yan D; Tang W
    Qual Life Res; 2024 Mar; 33(3):753-765. PubMed ID: 38079024
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Value of a QALY and VSI estimated with the chained approach.
    Olofsson S; Gerdtham UG; Hultkrantz L; Persson U
    Eur J Health Econ; 2019 Sep; 20(7):1063-1077. PubMed ID: 31172400
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Estimating the monetary value of a Quality-Adjusted Life-Year in Quebec.
    Kouakou CRC; He J; Poder TG
    Eur J Health Econ; 2024 Jul; 25(5):787-811. PubMed ID: 37656261
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Study of Patients' Willingness to Pay for a Cure of Chronic Obstructive Pulmonary Disease in Taiwan.
    Chen YT; Ying YH; Chang K; Hsieh YH
    Int J Environ Res Public Health; 2016 Mar; 13(3):. PubMed ID: 26938547
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Willingness to pay for quality and length of life gains in end of life patients of different ages.
    Reckers-Droog V; van Exel J; Brouwer W
    Soc Sci Med; 2021 Jun; 279():113987. PubMed ID: 33975052
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is there a kink in consumers' threshold value for cost-effectiveness in health care?
    O'Brien BJ; Gertsen K; Willan AR; Faulkner LA
    Health Econ; 2002 Mar; 11(2):175-80. PubMed ID: 11921315
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Estimating the willingness to pay for a quality-adjusted life year in Thailand: does the context of health gain matter?
    Thavorncharoensap M; Teerawattananon Y; Natanant S; Kulpeng W; Yothasamut J; Werayingyong P
    Clinicoecon Outcomes Res; 2013; 5():29-36. PubMed ID: 23345984
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Willingness to pay for one quality-adjusted life year in Iran.
    Moradi N; Rashidian A; Nosratnejad S; Olyaeemanesh A; Zanganeh M; Zarei L
    Cost Eff Resour Alloc; 2019; 17():4. PubMed ID: 30867654
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Exploring the willingness to pay for a quality-adjusted life-year in the state of Penang, Malaysia.
    Shafie AA; Lim YW; Chua GN; Hassali MA
    Clinicoecon Outcomes Res; 2014; 6():473-81. PubMed ID: 25364267
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Testing the convergent validity of the contingent valuation and travel cost methods in valuing the benefits of health care.
    Clarke PM
    Health Econ; 2002 Mar; 11(2):117-27. PubMed ID: 11921310
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The willingness to pay for in vitro fertilization: a pilot study using contingent valuation.
    Neumann PJ; Johannesson M
    Med Care; 1994 Jul; 32(7):686-99. PubMed ID: 8028404
    [TBL] [Abstract][Full Text] [Related]  

  • 40. International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness?
    Shiroiwa T; Sung YK; Fukuda T; Lang HC; Bae SC; Tsutani K
    Health Econ; 2010 Apr; 19(4):422-37. PubMed ID: 19382128
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.